Amylyx Pharmaceuticals received FDA Fast Track designation on August 7, 2025, for treatments aimed at ALS, including evaluating avexitide post-RYGB surgery.
3 reports, 1 independent
Updated Aug 8
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amylyx Pharmaceuticals received FDA Fast Track designation on August 7, 2025, for treatments aimed at ALS, including evaluating avexitide post-RYGB surgery.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Avexitide received FDA Breakthrough Therapy designation.Sub-event
Amylyx receives FDA Fast Track designation for ALS treatments, including avexitide post-RYGB.1 source
Keep exploring
The entities involved
-
Amylyx Pharmaceuticals
American biopharmaceutical company
Nothing else this week.
-
Als
river in Vienna
Nothing else this week.
Related events
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- Inceptua Group and TikoMed AB are collaborating on an investigational drug for progressive neurodegenerative disorders, including ALS.
- Amylyx Pharmaceuticals shares surged following the announcement of successful clinical trial results.
Coverage
Newest first; wire copies grouped- Business WireAmylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results Completion of recruitment for pivotal Phase 3 LUCIDITY trial of avexitide in PBH expected in 2025, with topline data anticipated i